Recursion Pharmaceuticals (RXRX) Projected to Post Quarterly Earnings on Monday

Recursion Pharmaceuticals (NASDAQ:RXRX) is anticipated to release its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.44) per share and revenue of $18.12 million for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.42) earnings per share. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Trading Up 3.6 %

NASDAQ:RXRX opened at $5.70 on Friday. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36. The stock’s 50 day simple moving average is $5.82 and its 200-day simple moving average is $6.75. The firm has a market cap of $2.29 billion, a P/E ratio of -3.73 and a beta of 1.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Hedge Funds Weigh In On Recursion Pharmaceuticals

An institutional investor recently raised its position in Recursion Pharmaceuticals stock. Brighton Jones LLC raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 49.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,261 shares of the company’s stock after purchasing an additional 6,699 shares during the period. Brighton Jones LLC’s holdings in Recursion Pharmaceuticals were worth $137,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

RXRX has been the topic of several research analyst reports. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Morgan Stanley decreased their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Finally, Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.